Peyronie's disease (PD) is a common condition which results in penile curvature making sexual intercourse difficult or impossible. Collagenase clostridium histolyticum (CCH) is the first licensed drug for the treatment of PD and is indicated in patients with palpable plaque and curvature deformity of at least 30° of curvature. However, only few monocentric studies are available in the current literature and this is the first national multicentric study focusing on this new treatment. In five Italian centres, 135 patients have completed the treatment with three injections of CCH using Ralph's shortened modified protocol. The protocol consisted of three intralesional injections of CCH (0.9 mg) given at 4-weekly intervals in addiction to a combination of home modelling, stretching and a vacuum device on a daily basis. An improvement in the angle of curvature was recorded in 128/135 patients (94.8%) by a mean (range) of 19.1 (0-40)° or 42.9 (0-67)% from baseline (p < 0.001). There was also a statistically significant improvement in all IIEF and PDQ questionnaires subdomains (p < 0.001 in all subdomains). This prospective multicentric study confirms that the three-injection protocol is effective enough to achieve a good result and to minimize the cost of the treatment.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Andrology. 2018 May 07 [Epub ahead of print]
M Capece, A Cocci, G Russo, G Cito, G Giubilei, G Cacciamani, G Garaffa, M Falcone, M Timpano, G Tasso, F Sessa, R Campi, F Di Maida, T Cai, G Morelli, B Giammusso, P Verze, A Palmieri, D Ralph, V Mirone, N Mondaini
Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Universita degli Studi di Napoli Federico II, Napoli, Italy., Department of Urology, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy., Department of Urology, Universita degli Studi di Catania Scuola di Facolta di Medicina, Catania, Italy., Department of Urology, Azienda USL Toscana centro Sede di Empoli, Empoli, Italy., Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy., The Institute of Urology, London, UK., Department of Urology, Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy., Department of Urology, Santa Chiara Hospital, Trento, Italy., Department of Urology, Università di Pisa, Pisa, Italy., Department of Urology, Ospedale Santa Maria Annunziata, Bagno a Ripoli, Italy.